Weekly Roundup: July 26-30

POLL: How do you feel about the recent FDA pipeline delays?

Shino Bay Aguilera, MD, Opens ABM Perspectives with a Bang

Opening the symposium in a circle of sparks and salsa dancing, Shino Bay Aguilera, MD, talks the importance of diversity and wellness in aesthetics.

Deep Dive into Microneedling with Energy-Based Devices

Victor Ross, MD, board-certified dermatologist and dermatologic surgeon in San Diego, California, spoke about different technologies available for microneedling and energy-based devices.

Reinforcing Your Aesthetic Practice Through Social Media

A group of expert panelists gathered to discuss how social media can benefit your practice and how to best use it to your advantage.

Camp Wonder Celebrates 20 Years

Camp Wonder, a camp that supports kids with skin disease and is sponsored by Galderma, is celebrating their 20th year of operations this week.

BioFactura Announces Commencement of Ustekinumab Biosimilar Phase 1 Trial

BFI-751, Biofactura’s biosimilar drug to ustekinumab will be investigated for the first time on human patients.

BioPhotas Announces Celluma RESTORE for Hair Loss

BioPhotas announces the new addition to their Celluma light therapy device line, Celluma RESTORE, for the treatment of hair loss, aging skin, and general pain.

Ellacor System Cleared by FDA

Cytrellis announced that the FDA has cleared the ellacor system to the treatment of moderate to severe wrinkles.

Twyneo Receives FDA Approval for Acne

Twyneo, a tretinoin and benzoyl peroxide cream, has been approved by the FDA for the treatment of acne vulgaris in patients 9 years and older.

FDA Approves Shingrix Vaccine for Immunocompromised Patients

The newest FDA indication allows for greater distribution to younger but equally vulnerable immunocompromised patients.

Smooth vs Hairy: What Causes Itch?

A study from the Georgia Institute of Technology examined the difference of itch in hairy vs nonhairy skin.

FDA Grants Orphan Drug Designation to Alrizomadlin for Stage IIB-IV Melanoma

The FDA has granted an orphan drug designation to alrizomadlin as a potential therapeutic option for patients with stage IIB-IV melanoma.

Dalbavancin Receives FDA Approval for ABSSSI in Children

Dalbavancin has received FDA approval to treat acute bacterial skin and skin structure infections in pediatric patients.

Amgen and IFPA Launch UPLIFT Innovation Challenge

Amgen and the International Federation of Psoriasis Associations have announced their efforts to combat the challenges of psoriasis.

Cartessa Launches Physiq for Noninvasive Body Contouring

Cartessa Aesthetics, LLC launched Physiq, its hands free, noninvasive body contouring device.

Physician Provides Update on Benzene Contamination in Sunscreens

In this exclusive video interview, Christopher Bunick, MD, PhD, gives Dermatology Times an update on benzene contamination being detected in various sunscreens and after-sun care products, as well as a recent recall by Johnson & Johnson.

Brace for Breakthroughs in Psoriasis, Psoriatic Arthritis

As COVID-19 eases, the FDA is breaking through its backlog and clinical trials are moving forward, opening the way for a new wave of treatments.

Acne Scar Armamentarium Melds Proven and Emerging Treatments

Here are best practices in understanding scar morphology, building patient trust, and choosing treatment.